Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: authors' response

Cornelis H van Werkhoven, Marieke Bolkenbaas, Susanne M Huijts, Theo J M Verheij, Marc J M Bonten

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Abstract

In response to Theilacker et al. we explain that we consider the point estimate as well as the confidence bounds in our interpretation of the study results and do not treat confidence intervals as a dichotomous signal. We refute that the proposed calculation of vaccine preventable disease incidence is more valuable than calculation of vaccine efficacy. Finally we remain at our conclusion that PCV13 vaccination in the elderly is unlikely to cause a relevant reduction in the incidence of CAP, LRTI, LRTI-related antibiotic use or total antibiotic use in primary care.

Original languageEnglish
Pages (from-to)926
Number of pages1
JournalClinical Microbiology and Infection
Volume27
Issue number6
Early online date6 Jan 2021
DOIs
Publication statusPublished - Jun 2021

Fingerprint

Dive into the research topics of 'Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: authors' response'. Together they form a unique fingerprint.

Cite this